Immunogenicity after the first dose of the BNT162b2 mRNA Covid-19 vaccine: real-world evidence from Greek healthcare workers

Real-world data regarding the effectiveness, safety and immunogenicity of the Pfizer-BioNTech BNT162b2 mRNA vaccine are accumulating in the literature, suggesting that this vaccine generates high titres of S1-binding IgG antibodies that exhibit potent virus neutralization capacity. This is the first...

Descripción completa

Detalles Bibliográficos
Autores principales: Kontopoulou, Konstantina, Ainatzoglou, Alexandra, Ifantidou, Athina, Nakas, Christos T., Gkounti, Georgia, Adamopoulos, Vasilios, Papadopoulos, Nikitas, Papazisis, Georgios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Microbiology Society 2021
Materias:
Prevention, Therapy and Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8513631/
https://www.ncbi.nlm.nih.gov/pubmed/34397348
http://dx.doi.org/10.1099/jmm.0.001387

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8513631/
https://www.ncbi.nlm.nih.gov/pubmed/34397348
http://dx.doi.org/10.1099/jmm.0.001387

Ejemplares similares